Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Diabetes Care. 2021 Mar;44(3):810-816. doi: 10.2337/dc20-1712. Epub 2021 Jan 6.
To study whether serum galectin-3 and other biomarkers of inflammation predict coronary heart disease (CHD) in subjects with long-standing childhood-onset type 1 diabetes.
A population-based nationwide cohort of 299 subjects with type 1 diabetes diagnosed in Norway at <15 years of age during 1973-1982 was examined in 2002-2003 at a mean age of 33 years (range 21-44), with mean diabetes duration of 24 years (range 19-30). Subjects were followed through 31 December 2017 for their first CHD event registered by a hospitalization or cause of death using nationwide registries. Stored serum samples were available for 296 subjects and analyzed for interleukin-6 (IL-6), IL-6 receptor, IL-18, hs-CRP, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), galectin-3, and high-sensitivity troponin T. Adjusted hazard ratios (aHRs) for CHD per SD increase in biomarker were estimated using Cox regression.
Of 295 subjects, 40 (13.6%) had a documented CHD event during a mean follow-up of 14.4 years (range 0.5-16). IL-6 (aHR 1.32 [95% CI 1.07-1.63]), galectin-3 (aHR 1.44 [95% CI 1.09-1.80]), and TIMP-1 (aHR 1.37 [95% CI 1.04-1.81]) were significant predictors of CHD after adjustment for conventional risk factors.
Galectin-3 was significantly associated with future CHD in subjects with type 1 diabetes, and if the results are replicated in larger studies, it may aid in prediction together with conventional risk factors for CHD.
研究血清半乳糖凝集素-3 和其他炎症生物标志物是否可预测长期儿童期起病 1 型糖尿病患者的冠心病（CHD）。
在 2002-2003 年，对挪威于 1973-1982 年期间在<15 岁时诊断为 1 型糖尿病的 299 例患者进行了一项基于人群的全国性队列研究，其平均年龄为 33 岁（范围为 21-44 岁），平均糖尿病病程为 24 年（范围为 19-30 年）。通过全国性登记处记录的住院或死因，对 31 日 2017 年之前首次 CHD 事件进行随访。对 296 例患者进行了储存血清样本分析，检测白细胞介素-6（IL-6）、IL-6 受体、IL-18、高敏 C 反应蛋白、基质金属蛋白酶-9、金属蛋白酶组织抑制剂-1（TIMP-1）、半乳糖凝集素-3 和高敏肌钙蛋白 T。使用 Cox 回归估计生物标志物每增加一个标准差的 CHD 调整后危险比（aHR）。
在 295 例患者中，有 40 例（13.6%）在平均 14.4 年（范围 0.5-16 年）的随访中发生了有记录的 CHD 事件。IL-6（aHR 1.32[95%CI 1.07-1.63]）、半乳糖凝集素-3（aHR 1.44[95%CI 1.09-1.80]）和 TIMP-1（aHR 1.37[95%CI 1.04-1.81]）在调整了传统危险因素后仍是 CHD 的显著预测因子。
半乳糖凝集素-3 与 1 型糖尿病患者未来 CHD 显著相关，如果在更大的研究中得到证实，它可能有助于与 CHD 的传统危险因素一起进行预测。
